Thoracic Drainage Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Thoracic Drainage Devices Market Trends and Insights

Rising Prevalence of Pleural Diseases

More than 1.5 million U.S. patient admissions per year require pleural drainage, and spontaneous pneumothorax is increasing 2.3% annually in adults aged ≥ 65.^{[1]Centers for Disease Control and Prevention, “Pleural Disease Surveillance,” cdc.gov} Similar momentum in Germany, France, and the UK shows a 4.1% rise in diagnoses between 2024 and 2025. Medicare payment reforms that reward same-day discharge are increasing outpatient small-bore catheter deployment, now accounting for 40% of ambulatory cases. Low-income regions continue to have a demand for cost-effective large-bore solutions, as tuberculosis-related empyema remains a common condition. Device design pivots toward 14-Fr or smaller indwelling catheters that balance comfort with flow efficiency.

Increasing Thoracic & Cardiac Surgery Volumes

Thoracic surgery volumes rebounded to 3.2 million procedures in 2025, surpassing pre-pandemic peaks by 7%. Cardiac-surgery procedures reached 2.8 million worldwide due to aging demographics, and China’s reimbursement approval for robotic thoracic interventions triggered a 12% uptick in minimally invasive cases. The U.S. bundled-payment model incentivizes hospitals to deploy digital drainage devices that shorten stays.^{[2]Centers for Medicare & Medicaid Services, “Bundled Payment Arrangement 2025,” cms.gov} However, Eastern Europe and Latin America lag as capital constraints and a limited surgical workforce suppress adoption.

Technological Advancements In Digital Drainage Systems

Digital platforms that integrate pressure and flow sensors reduce nursing workload by 30% per patient day. Medtronic’s Thopaz+ gained FDA clearance for ECMO support in 2024, while Getinge’s Atrium Ocean predicts removal readiness with 89% accuracy in German trials. Japan introduced an add-on reimbursement in 2025, which increased digital penetration to 18% of thoracic surgeries within six months. Upfront prices remain 3-5 times those of analog units, although rental programs at EUR 150 per episode are emerging in Germany to ease budget pressures.

Growing Adoption of Minimally-Invasive & Robotic Procedures

Robotic-assisted lobectomy accounted for 22% of U.S. cases in 2025, up from 15% in 2024. These techniques favor 12-Fr to 14-Fr tubes, enabling shorter immobilization times. Europe’s demand for auditable outcome data under its Medical Device Regulation increases the utilization of digital drainage. South Korea expanded robotic-surgery coverage to 12 thoracic indications in 2024, resulting in a 19% year-over-year increase in minimally invasive procedures.

High Cost of Advanced Digital Systems

Digital units list at USD 2,500–4,000 versus USD 600–800 for analog, restricting uptake in India where only 8% of hospitals deploy them. Brazil’s fixed reimbursement lacks differentiation, disincentivizing upgrades. The UK negotiated a 22% discount to maintain cost neutrality, taking into account nursing savings. Rental models ease barriers, yet the total cost of ownership stays 40–60% higher.

Stringent Regulatory Approvals & Recalls

Fourteen FDA Class II recalls in 2024–2025 highlighted catheter-tip separation and canister failures.^{[3]U.S. Food and Drug Administration, “Medical Device Recalls 2024-2025,” fda.gov} Europe’s MDR re-certification costs average EUR 500,000 per product line, delaying 23 launches by early 2026. China’s unannounced factory inspections added a four-month approval lag.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Kits Gain as Efficiency Trumps Customization

Chest drainage systems accounted for 37.81% of the revenue in 2025. In contrast, thoracic drainage kits, valued for their sterilized convenience, are projected to outpace the market at a 6.38% CAGR, driven by ASC demand. Small-bore pleural catheters (≤14 Fr) predominate in the outpatient management of malignant effusions, whereas large-bore variants remain crucial for the treatment of trauma and empyema. Digital systems, though fewer in unit shipments, command 40–50% price premiums and lock in disposable revenue. 

By Material Composition: Polyurethane Closes the Gap on Silicone

Silicone represented 46.13% of material revenue, favored for biocompatibility. Polyurethane is closing the gap with a 6.81% annual growth rate, aided by thin-wall extrusion technologies. PVC’s share of the thoracic drainage devices market size is expected to drop below 10% by 2031 as regulatory curbs escalate. Advanced polymers such as antimicrobial-coated polyurethane reduce infections by 38%, supporting a 30% price premium.

By Application: Oncology Rises as Cardiac Surgery Plateaus

Cardiac surgery held 29.85% of the thoracic drainage devices market share in 2025, but this is expected to slow as transcatheter interventions reduce chest-tube dwell time. Oncology and pain management advance at a rate of 5.58% annually, reflecting the prevalence of malignant pleural effusion in approximately 150,000 U.S. patients each year. Trauma and infectious disease segments remain steady in emerging economies.

By End User: Ambulatory Centers Disrupt Hospital Dominance

Hospitals retained 54.06% revenue in 2025. However, ASC volumes climb at 8.05% as Medicare adds 18 thoracic procedures to its approved list. Home healthcare, though smallest, is expanding rapidly as portable devices enable remote management and 31% global placement growth of PleurX catheters in 2025.

Geography Analysis

North America’s thoracic drainage devices market share was 39.64% in 2025, as digital platforms gained penetration in academic centers above 22%. Medicare’s Hospital-at-Home expansion accelerated demand for portable catheters, while Canada piloted digital devices to cut ICU stays. Germany’s DRG system favors analog systems, whereas the UK negotiated national contracts that bundle device cost with reduced nursing time. France and Italy expanded surgical capacity via public-private partnerships, although expenditure caps limit digital conversion. 

The Asia-Pacific market is expected to grow at a 7.32% annual rate through 2031. China is establishing 120 thoracic centers under the Healthy China 2030 initiative, which is funded by the government. India’s procedure volumes increased by 19% after the inclusion of Ayushman Bharat reimbursement. Japan and South Korea’s expansion of robotic-surgery coverage further boosts demand for small-bore catheters. 

Regulatory Landscape

Thoracic drainage devices are largely regulated as moderate-risk products, and the United States commonly classifies chest drainage-related devices under FDA Class II (special controls), with market access typically through the 510(k) pathway. Post-market oversight has remained prominent, with multiple FDA Class II recalls across 2024-2025 tied to issues such as catheter-tip separation and canister failures. These recalls continue to reinforce supplier emphasis on design controls, traceability, and complaint handling.

In Europe, the Medical Device Regulation (MDR) continues to raise clinical evidence and recertification burdens, with re-certification costs averaging around EUR 500,000 per product line and launch timing impacts extending into early 2026. A system-level adjustment was signaled on December 16, 2025, when the European Commission published proposed amendments (COM(2025)1023) to MDR and IVDR to address implementation bottlenecks. Across markets, manufacturers also align product and quality documentation to recognized standards such as ISO 20697:2018 for sterile single-use drainage catheters and ISO 10079-1:2015 for electrically powered drainage equipment, supporting tender eligibility and hospital procurement qualification.

Market Opportunities and Future Outlook

White space is widening around digitized chest drainage workflows that convert analog observations into auditable, objective data for clinical decision-making and procurement justification. FDA 510(k) clearance in March 2025 for ATMOS Inc.'s ATMOS C 051 Cardiothoracic Digital Drain and Observation System adds another commercial digital platform for ICU, thoracic surgery, and ECMO protocols, and it reinforces a shift toward device telemetry that standardizes chest tube removal decisions. Clinical literature comparing suction strategies and intrathoracic pressure settings on digital systems also supports pathway redesign in uncomplicated cases, which increases demand for devices that can capture pressure and air-leak trends consistently.

Opportunities also sit in hybrid and portable configurations that bridge inpatient and ambulatory settings, especially as ambulatory surgical centers expand procedure volumes faster than hospitals and same-day discharge incentives support small-bore catheter use. Purchasing criteria and product development increasingly hinge on (1) interoperability with hospital documentation needs, including objective data export for outcome tracking under tighter audit requirements, (2) compact, alarm-enabled devices for step-down and outpatient monitoring, and (3) material substitution away from PVC toward silicone, polyurethane, and advanced polymers that align with sustainability mandates and infection-control priorities. Vendors that pair digital consoles with recurring disposable ecosystems and offer flexible acquisition models, including episode-based programs seen in parts of Europe, can enter cost-constrained facilities without relying only on capital budgets.